CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy

References

• Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012); 12:269-81; PMID:22437939; http://dx.doi.org/10.1038/nri3191
   PubMed Web of Science ®Google Scholar
• Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity (2013); 39:61-73; PMID:23890064; http://dx.doi.org/10.1016/j.immuni.2013.07.005
   PubMed Web of Science ®Google Scholar
• Kalinski P, Okada H. Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors. Semin Immunol (2010); 22:173-82; PMID:20409732; http://dx.doi.org/10.1016/j.smim.2010.03.002
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012); 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• John LB, Howland LJ, Flynn JK, West AC, Devaud C, Duong CP, Stewart TJ, Westwood JA, Guo ZS, Bartlett DL et al. Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res (2012); 72:1651-60; PMID:22315352; http://dx.doi.org/10.1158/0008-5472.CAN-11-2788
   PubMed Web of Science ®Google Scholar
• Diaconu I, Cerullo V, Hirvinen ML, Escutenaire S, Ugolini M, Pesonen SK, Bramante S, Parviainen S, Kanerva A, Loskog AS et al. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res (2012); 72:2327-38; PMID:22396493; http://dx.doi.org/10.1158/0008-5472.CAN-11-2975
   PubMed Web of Science ®Google Scholar
• Willmon CL, Saloura V, Fridlender ZG, Wongthida P, Diaz RM, Thompson J, Kottke T, Federspiel M, Barber G, Albelda SM et al. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res (2009); 69:7713-20; PMID:19773437; http://dx.doi.org/10.1158/0008-5472.CAN-09-1013
   PubMed Web of Science ®Google Scholar
• Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res (1998); 58:3491-4; PMID:9721846
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003); 348:203-13; PMID:12529460; http://dx.doi.org/10.1056/NEJMoa020177
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006); 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139
   PubMed Web of Science ®Google Scholar
• Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene (2010); 29:1093-102; PMID:19946335; http://dx.doi.org/10.1038/onc.2009.416
   PubMed Web of Science ®Google Scholar
• Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene (2008); 27:5904-12; PMID:18836471; http://dx.doi.org/10.1038/onc.2008.271
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013); 14:1014-22; PMID:24048123; http://dx.doi.org/10.1038/ni.2703
   PubMed Web of Science ®Google Scholar
• Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y, Guo ZS. Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer (2013); 12:103; PMID:24020520; http://dx.doi.org/10.1186/1476-4598-12-103
   PubMed Web of Science ®Google Scholar
• Chiocca EA, Rabkin SD. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res (2014); 2:295-300; PMID:24764576; http://dx.doi.org/10.1158/2326-6066.CIR-14-0015
   PubMed Web of Science ®Google Scholar
• Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer (2014); 14:559-67; PMID:24990523; http://dx.doi.org/10.1038/nrc3770
   PubMed Web of Science ®Google Scholar
• Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I, Erbs P, Limacher JM, Preville X, Zitvogel L et al. Trial Watch: Oncolytic viruses for cancer therapy. Oncoimmunology (2014); 3:e28694; PMID:25097804; http://dx.doi.org/10.4161/onci.28694
   PubMed Web of Science ®Google Scholar
• Bromley SK, Mempel TR, Luster AD. Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol (2008); 9:970-80; PMID:18711434; http://dx.doi.org/10.1038/ni.f.213
   PubMed Web of Science ®Google Scholar
• Forster R, Schubel A, Breitfeld D, Kremmer E, Renner-Muller I, Wolf E, Lipp M. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell (1999); 99:23-33; PMID:10520991; http://dx.doi.org/10.1016/S0092-8674(00)80059-8
   PubMed Web of Science ®Google Scholar
• Nesbeth Y, Scarlett U, Cubillos-Ruiz J, Martinez D, Engle X, Turk MJ, Conejo-Garcia JR. CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion. Cancer Res (2009); 69:6331-8; PMID:19602595; http://dx.doi.org/10.1158/0008-5472.CAN-08-4329
   PubMed Web of Science ®Google Scholar
• Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol (1998); 161:927-32; PMID:9670971
   PubMed Web of Science ®Google Scholar
• Kanegane C, Sgadari C, Kanegane H, Teruya-Feldstein J, Yao L, Gupta G, Farber JM, Liao F, Liu L, Tosato G. Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J Leukoc Biol (1998); 64:384-92; PMID:9738666
   PubMed Web of Science ®Google Scholar
• Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP, Lin W, Boyd JG, Moser B, Wood DE et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med (1998); 187:2009-21; PMID:9625760; http://dx.doi.org/10.1084/jem.187.12.2009
   PubMed Web of Science ®Google Scholar
• Hensbergen PJ, Wijnands PG, Schreurs MW, Scheper RJ, Willemze R, Tensen CP. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis. J Immunother (2005); 28:343-51; PMID:16000952; http://dx.doi.org/10.1097/01.cji.0000165355.26795.27
   PubMed Web of Science ®Google Scholar
• Hamilton NH, Mahalingam S, Banyer JL, Ramshaw IA, Thomson SA. A recombinant vaccinia virus encoding the interferon-inducible T-cell alpha chemoattractant is attenuated in vivo. Scand J Immunol (2004); 59:246-54; PMID:15030574; http://dx.doi.org/10.1111/j.0300-9475.2004.01391.x
   PubMed Web of Science ®Google Scholar
• Berencsi K, Meropol NJ, Hoffman JP, Sigurdson E, Giles L, Rani P, Somasundaram R, Zhang T, Kalabis J, Caputo L et al. Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic culture. Cancer Immunol Immunother (2007); 56:359-70; PMID:16783574; http://dx.doi.org/10.1007/s00262-006-0190-2
   PubMed Web of Science ®Google Scholar
• Wendel M, Galani IE, Suri-Payer E, Cerwenka A. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res (2008); 68:8437-45; PMID:18922917; http://dx.doi.org/10.1158/0008-5472.CAN-08-1440
   PubMed Web of Science ®Google Scholar
• Li J, O'Malley M, Urban J, Sampath P, Guo ZS, Kalinski P, Thorne SH, Bartlett DL. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther (2011); 19:650-7; PMID:21266959; http://dx.doi.org/10.1038/mt.2010.312
   PubMed Web of Science ®Google Scholar
• Gregoire M. What's the place of immunotherapy in malignant mesothelioma treatments? Cell Adh Migr (2010); 4:153-61; PMID:20179421; http://dx.doi.org/10.4161/cam.4.1.11361
   PubMed Web of Science ®Google Scholar
• Swartz MA, Iida N, Roberts EW, Sangaletti S, Wong MH, Yull FE, Coussens LM, DeClerck YA. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res (2012); 72:2473-80; PMID:22414581; http://dx.doi.org/10.1158/0008-5472.CAN-12-0122
   PubMed Web of Science ®Google Scholar
• Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res (2007); 13:5256-61; PMID:17875753; http://dx.doi.org/10.1158/1078-0432.CCR-07-0892
   PubMed Web of Science ®Google Scholar
• Abastado JP. The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor. Cancer Res (2012); 72:2159-61; PMID:22549945; http://dx.doi.org/10.1158/0008-5472.CAN-11-3538
   PubMed Web of Science ®Google Scholar
• Boozari B, Mundt B, Woller N, Struver N, Gurlevik E, Schache P, Kloos A, Knocke S, Manns MP, Wirth TC et al. Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma. Gut (2010); 59:1416-26; PMID:20675696; http://dx.doi.org/10.1136/gut.2009.196519
   PubMed Web of Science ®Google Scholar
• Donnelly OG, Errington-Mais F, Steele L, Hadac E, Jennings V, Scott K, Peach H, Phillips RM, Bond J, Pandha H et al. Measles virus causes immunogenic cell death in human melanoma. Gene Ther (2013); 20:7-15; PMID:22170342; http://dx.doi.org/10.1038/gt.2011.205
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Inoue H, Nakamura T, Yamada M, Sakamoto C, Urata Y, Okazaki T, Marumoto T, Takahashi A, Takayama K et al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res (2012); 72:2609-21; PMID:22461509; http://dx.doi.org/10.1158/0008-5472.CAN-11-3185
   PubMed Web of Science ®Google Scholar
• Guillerme JB, Boisgerault N, Roulois D, Menager J, Combredet C, Tangy F, Fonteneau JF, Gregoire M. Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells. Clin Cancer Res (2013); 19:1147-58; PMID:23339127; http://dx.doi.org/10.1158/1078-0432.CCR-12-2733
   PubMed Web of Science ®Google Scholar
• Fonteneau JF, Guillerme JB, Tangy F, Gregoire M. Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells. Oncoimmunology (2013); 2:e24212; PMID:23762802; http://dx.doi.org/10.4161/onci.24212
   PubMedGoogle Scholar
• Berwin B, Reed RC, Nicchitta CV. Virally induced lytic cell death elicits the release of immunogenic GRP94/gp96. J Biol Chem (2001); 276:21083-8; PMID:11279246; http://dx.doi.org/10.1074/jbc.M101836200
   PubMed Web of Science ®Google Scholar
• Guo ZS, Naik A, O'Malley ME, Popovic P, Demarco R, Hu Y, Yin X, Yang S, Zeh HJ, Moss B et al. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res (2005); 65:9991-8; PMID:16267024; http://dx.doi.org/10.1158/0008-5472.CAN-05-1630
   PubMed Web of Science ®Google Scholar
• Whilding LM, Archibald KM, Kulbe H, Balkwill FR, Oberg D, McNeish IA. Vaccinia virus induces programmed necrosis in ovarian cancer cells. Mol Ther (2013); 21:2074-86; PMID:23985697; http://dx.doi.org/10.1038/mt.2013.195
   PubMed Web of Science ®Google Scholar
• Guo ZS, Liu Z, Bartlett DL. Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity. Front Oncol (2014); 4:74; PMID:24782985; http://dx.doi.org/10.3389/fonc.2014.00074.
   PubMedGoogle Scholar
• Workenhe ST, Mossman KL. Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol Ther (2014); 22:251-6; PMID:24048442; http://dx.doi.org/10.1038/mt.2013.220
   PubMed Web of Science ®Google Scholar
• Xiao H, Peng Y, Hong Y, Huang L, Guo ZS, Bartlett DL, Fu N, Munn DH, Mellor A, He Y. Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization. J Immunol (2013); 190:5866-73; PMID:23610140; http://dx.doi.org/10.4049/jimmunol.1203470
   PubMed Web of Science ®Google Scholar
• Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet (2008); 371:771-83; PMID:18275997; http://dx.doi.org/10.1016/S0140-6736(08)60241-X
   PubMed Web of Science ®Google Scholar
• Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2012); 72:917-27; PMID:22186141; http://dx.doi.org/10.1158/0008-5472.CAN-11-1620
   PubMed Web of Science ®Google Scholar
• Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med (2013); 19:329-36; PMID:23396206; http://dx.doi.org/10.1038/nm.3089
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS et al. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol (2015); 33:2780-8; PMID:26014293; http://dx.doi.org/10.1200/JCO.2014.58.3377
   PubMed Web of Science ®Google Scholar
• Zeh HJ, Downs-Canner S, McCart JA, Guo ZS, Rao UN, Ramalingam L, Thorne SH, Jones HL, Kalinski P, Wieckowski E et al. First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity. Mol Ther (2015); 23:202-14; PMID:25292189; http://dx.doi.org/10.1038/mt.2014.194
   PubMed Web of Science ®Google Scholar
• Davis MR, Manning LS, Whitaker D, Garlepp MJ, Robinson BW. Establishment of a murine model of malignant mesothelioma. Int J Cancer (1992); 52:881-6; PMID:1459729; http://dx.doi.org/10.1002/ijc.2910520609
   PubMed Web of Science ®Google Scholar
• Thirunavukarasu P, Sathaiah M, Gorry MC, O'Malley ME, Ravindranathan R, Austin F, Thorne SH, Guo ZS, Bartlett DL. A rationally designed A34R mutant oncolytic poxvirus: improved efficacy in peritoneal carcinomatosis. Mol Ther (2013); 21:1024-33; PMID:23439499; http://dx.doi.org/10.1038/mt.2013.27
   PubMed Web of Science ®Google Scholar